The Government prohibits the export of drugs containing production, Tapentadol and Carisoprodol to the plant. Announced in the ministry in January that the central group (CDSCO). Medicines for drugs and exports covering the “Inspection Observing Based on Exports of India’s NDP drug exports, the Ministry of Health stated in its opinion.

Medicines for authorities (active drugs) tapentadol and Carisoprodol. “Communication has been sent to all state drug surveillance authorities and zones in order to grant the combination of Tapenadol and Carisoprodol for all export NOC and manufacturing licenses.

The same communication has also been sent to all ports reported from all said products via CSCO port agencies “.The Board of Directors is still caught up in 125 mg Carisoprodol. In a special number. CSCO tablets are accepted separately on 100 tablets. And neither of these drugs was included in the NDPS list, ”the Ministry of Health said.

It is also planned that CDSCO updates the export -NOC checklist to ensure that either the acceptance of the National Regulatory Authority (NRA) product registration certificate or the approval of the Indian regulatory authority or CSCO is required for all drugs used in India. Devesh Malladi, chairman of the Indian Drug Manufacturers Association (Idma) NDPS Committee, said: “This combination of Tapenadol and Carisoprodol is irrational and strange.

It is not accepted in any world. It can be manufactured by small pharmaceutical companies, not larger. In my opinion, manufacturers have no financial impact on the ban in this combination. It’s good that DCGI has denied the combination. “He added that the research question is to find out how these drugs were taken and how imported land allows imports. ”This update of the checklist deals with the root cause of the problem and resolves the problem permanently.

The government ensures that legal medicines are fluent to support health care worldwide and to manage these abnormalities vigorously through rapid and strong action, as shown through their recent decisions and activities, ”said the Ministry of Health. In December 2022, the government launched risk-based inspections of medication manufacturing and testing attempts to ensure the regulation of the drug. Since then, 905 units have been revised, leading to 694 cases.

These measures include STOP production orders (SPO), end test (STO), suspension/cancellation/cancellations, warning letters and notifications depending on the severity of the failure. This initiative has given valuable views on manufacturing practices and has resulted in corrective action, leading to significant improvements in the regulatory framework. The government will continue to monitor and regulate drug exports to protect India’s drug abuse, the ministry added.

Source https://www.hindustantimes.com/cities/mumbai-news/authorities-crack-down-on-pharma-firms-amid-ban-on-addictive-opioids-101740510783593.html

https://www.livemint.com/industry/govt-bans-production-export-of-drugs-containing-tapentadol-and-carisoprodol-drug-abuse-west-africa-opioid-crisis-11740313018961.html